The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
Pharmaceutical compositions having hypolipidaemic and/or hypoglycaemic activity, contain a substituted (4-carboxyphenoxy) phenyl alkane derivative.
具有降脂和/或降血糖活性的药物组合物,包含一种取代的(4-羧基苯氧基)苯基烷衍生物。
Polycyclic oxy-aromatic acid
申请人:Beecham Group Limited
公开号:US04098816A1
公开(公告)日:1978-07-04
Pharmaceutical compositions having hypolipidaemic and/or hypoglycaemic activity, contain a substituted (4-carboxyphenoxy) phenyl alkane derivative.
具有降脂和/或降糖活性的药物组合物,包含一种取代的(4-羧基苯氧基)苯基烷衍生物。
Substituted benzopyrans as selective estrogen receptor-beta agonists
申请人:Durst Lee Gregory
公开号:US20070106082A1
公开(公告)日:2007-05-10
This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have the formula: (I)